StreetInsider.com News Articles

JPMorgan Starts Larimar Therapeutics (LRMR) at Overweight

Wed, 27 May 2026 01:09:42 -0400

JPMorgan analyst Tessa Romero initiates coverage on Larimar Therapeutics (NASDAQ: LRMR) with a Overweight rating and a price target of $9.00.

The analyst comments: “We are initiating coverage of Larimar Therapeutics (LRMR) with an Overweight rating and a Dec 2027 price target of $9. Larimar’s lead asset is nomlabofusp (nomla; CTI-1601), a subcutaneously administered, recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich’s ataxia (FA), a rare neurodegenerative disorder. In the near-term, in 2Q26, we expect to see topline results from the ongoing open-label (OL) study as well as feedback from the company’s type B

JPMorgan Starts Larimar Therapeutics (LRMR) at Overweight

Wed, 27 May 2026 01:09:42 -0400

JPMorgan analyst Tessa Romero initiates coverage on Larimar Therapeutics (NASDAQ: LRMR) with a Overweight rating and a price target of $9.00.

Form 4 Larimar Therapeutics, For: May 19 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P.

Wed, 20 May 2026 20:03:00 -0400

si-local-file:///var/storage/secattach/20260520/26529969.html

Form 4 Larimar Therapeutics, For: May 19 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P.

Wed, 20 May 2026 20:03:00 -0400

si-local-file:///var/storage/secattach/20260520/26529969.html

Form 4 Larimar Therapeutics, For: May 19 Filed by: LEFF JONATHAN S

Wed, 20 May 2026 18:04:00 -0400

si-local-file:///var/storage/secattach/20260520/26529768.html

Form 4 Larimar Therapeutics, For: May 19 Filed by: LEFF JONATHAN S

Wed, 20 May 2026 18:04:00 -0400

si-local-file:///var/storage/secattach/20260520/26529768.html

Form 4 Larimar Therapeutics, For: May 19 Filed by: SHERMAN JEFFREY W

Wed, 20 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260520/26528878.html

Form 4 Larimar Therapeutics, For: May 19 Filed by: SHERMAN JEFFREY W

Wed, 20 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260520/26528878.html

Form 4 Larimar Therapeutics, For: May 19 Filed by: Truitt Joseph

Wed, 20 May 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260520/26528788.html

Form 4 Larimar Therapeutics, For: May 19 Filed by: Truitt Joseph

Wed, 20 May 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260520/26528788.html

Form 4 Larimar Therapeutics, For: May 19 Filed by: THOMAS FRANK E

Wed, 20 May 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260520/26528748.html

Form 4 Larimar Therapeutics, For: May 19 Filed by: THOMAS FRANK E

Wed, 20 May 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260520/26528748.html

Form 4 Larimar Therapeutics, For: May 19 Filed by: Hamilton Thomas Edward

Wed, 20 May 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260520/26528702.html

Form 4 Larimar Therapeutics, For: May 19 Filed by: Hamilton Thomas Edward

Wed, 20 May 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260520/26528702.html

Form 8-K Larimar Therapeutics, For: May 19

Tue, 19 May 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260519/26521622.html

Form 8-K Larimar Therapeutics, For: May 19

Tue, 19 May 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260519/26521622.html

Larimar Therapeutics (LRMR) Reiterated at Market Outperform by Citizens

Fri, 15 May 2026 05:03:30 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $18.00 price target on Larimar Therapeutics (NASDAQ: LRMR).

The analyst commented, "LRMR shares are up just 8% YTD with the stock pulling back since nomlabofusp was granted Breakthrough Therapy designation in late February and the company strengthened its balance sheet with an upsized equity offering. Since then, we have seen new peer-reviewed preclinical data linking skin frataxin to FA-relevant organs, which addresses a central clinical and regulatory question. Importantly, FDA had already reviewed the data, which were a key factor underpinning the agency's willingness to consider skin frataxin as a reasonably

Form SCHEDULE 13G/A Larimar Therapeutics, Filed by: Blue Owl Capital Holdings LP

Thu, 14 May 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260514/26495476.html

Form SCHEDULE 13G/A Larimar Therapeutics, Filed by: Blue Owl Capital Holdings LP

Thu, 14 May 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260514/26495476.html

Form 10-Q Larimar Therapeutics, For: Mar 31

Thu, 14 May 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260514/26495313.html

Form 10-Q Larimar Therapeutics, For: Mar 31

Thu, 14 May 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260514/26495313.html

Larimar Therapeutics, Inc. (LRMR) Tops Q1 EPS by 22c

Thu, 14 May 2026 07:34:19 -0400

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q1 EPS of ($0.31), $0.22 better than the analyst estimate of ($0.53).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

Form 8-K Larimar Therapeutics, For: May 14

Thu, 14 May 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260514/26489754.html

Form 8-K Larimar Therapeutics, For: May 14

Thu, 14 May 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260514/26489754.html

Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update

Thu, 14 May 2026 07:00:00 -0400

Intending to initiate rolling BLA seeking accelerated approval with submission of nonclinical and clinical modules in June 2026; submission of the final modules including the CMC module expected in second half of 2026
Cross-species nonclinical findings that support skin frataxin levels as a surrogate endpoint for nomlabofusp program published in peer-reviewed journal
Topline open label study data to support BLA submission expected in Q2 2026
$200.4 million in cash, cash equivalents and marketable securities as of March 31, 2026, with projected cash runway into the second quarter of 2027

BALA CYNWYD, Pa., May